124 results on '"F. Camou"'
Search Results
2. External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection
- Author
-
Bernard Surial, Adrià Ramírez Mena, Marie Roumet, Andreas Limacher, Colette Smit, Olivier Leleux, Amanda Mocroft, Marc van der Valk, Fabrice Bonnet, Lars Peters, Jürgen K. Rockstroh, Huldrych F. Günthard, Annalisa Berzigotti, Andri Rauch, Gilles Wandeler, I. Abela, K. Aebi-Popp, A. Anagnostopoulos, M. Battegay, E. Bernasconi, D.L. Braun, H.C. Bucher, A. Calmy, M. Cavassini, A. Ciuffi, G. Dollenmaier, M. Egger, L. Elzi, J. Fehr, J. Fellay, H. Furrer, C.A. Fux, H.F. Günthard, A. Hachfeld, D. Haerry, B. Hasse, H.H. Hirsch, M. Hoffmann, I. Hösli, M. Huber, D. Jackson-Perry, C.R. Kahlert, L. Kaiser, O. Keiser, T. Klimkait, R.D. Kouyos, H. Kovari, K. Kusejko, N. Labhardt, K. Leuzinger, Martinez de Tejada B, C. Marzolini, K.J. Metzner, N. Müller, J. Nemeth, D. Nicca, J. Notter, P. Paioni, G. Pantaleo, M. Perreau, A. Rauch, L. Salazar-Vizcaya, P. Schmid, R. Speck, M. Stöckle, P. Tarr, A. Trkola, G. Wandeler, M. Weisser, S. Yerly, M. van der Valk, S.E. Geerlings, A. Goorhuis, V.C. Harris, J.W. Hovius, B. Lempkes, F.J.B. Nellen, T. van der Poll, J.M. Prins, V. Spoorenberg, M. van Vugt, W.J. Wiersinga, F.W.M.N. Wit, C. Bruins, J. van Eden, I.J. Hylkema-van den Bout, A.M.H. van Hes, F.J.J. Pijnappel, S.Y. Smalhout, A.M. Weijsenfeld, N.K.T. Back, B. Berkhout, M.T.E. Cornelissen, R. van Houdt, M. Jonges, S. Jurriaans, C.J. Schinkel, K.C. Wolthers, H.L. Zaaijer, E.J.G. Peters, M.A. van Agtmael, R.S. Autar, M. Bomers, K.C.E. Sigaloff, M. Heitmuller, L.M. Laan, M. van den Berge, A. Stegeman, S. Baas, L. Hage de Looff, A. van Arkel, J. Stohr, B. Wintermans, M.J.H. Pronk, H.S.M. Ammerlaan, E.S. de Munnik, B. Deiman, A.R. Jansz, V. Scharnhorst, J. Tjhie, M.C.A. Wegdam, A. van Eeden, E. Hoornenborg, J. Nellen, W. Alers, L.J.M. Elsenburg, H. Nobel, M.E.E. van Kasteren, M.A.H. Berrevoets, A.E. Brouwer, B.A.F.M. de Kruijf-van de Wiel, A. Adams, M. Pawels-van Rijkevoorsel, A.G.M. Buiting, J.L. Murck, C. Rokx, A.A. Anas, H.I. Bax, E.C.M. van Gorp, M. de Mendonça Melo, E. van Nood, J.L. Nouwen, B.J.A. Rijnders, C.A.M. Schurink, L. Slobbe, T.E.M.S. de Vries-Sluijs, N. Bassant, J.E.A. van Beek, M. Vriesde, L.M. van Zonneveld, J. de Groot, J.J.A. van Kampen, M.P.G. Koopmans, J.C. Rahamat-Langendoen, J. Branger, R.A. Douma, A.S. Cents-Bosma, C.J.H.M. Duijf-van de Ven, E.F. Schippers, C. van Nieuwkoop, J. Geilings, S. van Winden, G. van der Hut, N.D. van Burgel, E.M.S. Leyten, L.B.S. Gelinck, F. Mollema, G.S. Wildenbeest, T. Nguyen, P.H.P. Groeneveld, J.W. Bouwhuis, A.J.J. Lammers, A.G.W. van Hulzen, S. Kraan, M.S.M. Kruiper, G.L. van der Bliek, P.C.J. Bor, S.B. Debast, G.H.J. Wagenvoort, A.H.E. Roukens, M.G.J. de Boer, H. Jolink, M.M.C. Lambregts, H. Scheper, W. Dorama, N. van Holten, E.C.J. Claas, E. Wessels, J.G. den Hollander, R. El Moussaoui, K. Pogany, C.J. Brouwer, D. Heida-Peters, E. Mulder, J.V. Smit, D. Struik-Kalkman, T. van Niekerk, O. Pontesilli, C. van Tienen, S.H. Lowe, A.M.L. Oude Lashof, D. Posthouwer, M.E. van Wolfswinkel, R.P. Ackens, K. Burgers, M. Elasri, J. Schippers, T.R.A. Havenith, M. van Loo, M.G.A. van Vonderen, L.M. Kampschreur, M.C. van Broekhuizen, null S, null Faber, A. Al Moujahid, G.J. Kootstra, C.E. Delsing, M. van der Burg-van de Plas, L. Scheiberlich, W. Kortmann, G. van Twillert, R. Renckens, J. Wagenaar, D. Ruiter-Pronk, F.A. van Truijen-Oud, J.W.T. Cohen Stuart, M. Hoogewerf, W. Rozemeijer, J.C. Sinnige, K. Brinkman, G.E.L. van den Berk, K.D. Lettinga, M. de Regt, W.E.M. Schouten, J.E. Stalenhoef, J. Veenstra, S.M.E. Vrouenraets, H. Blaauw, G.F. Geerders, M.J. Kleene, M. Knapen, M. Kok, I.B. van der Meché, A.J.M. Toonen, S. Wijnands, E. Wttewaal, D. Kwa, T.J.W. van de Laar, R. van Crevel, K. van Aerde, A.S.M. Dofferhoff, S.S.V. Henriet, H.J.M. ter Hofstede, J. Hoogerwerf, O. Richel, M. Albers, K.J.T. Grintjes-Huisman, M. de Haan, M. Marneef, M. McCall, D. Burger, E.H. Gisolf, M. Claassen, R.J. Hassing, G. ter Beest, P.H.M. van Bentum, M. Gelling, Y. Neijland, C.M.A. Swanink, M. Klein Velderman, S.F.L. van Lelyveld, R. Soetekouw, L.M.M. van der Prijt, J. van der Swaluw, J.S. Kalpoe, A. Wagemakers, A. Vahidnia, F.N. Lauw, D.W.M. Verhagen, M. van Wijk, W.F.W. Bierman, M. Bakker, R.A. van Bentum, M.A. van den Boomgaard, J. Kleinnijenhuis, E. Kloeze, A. Middel, D.F. Postma, H.M. Schenk, Y. Stienstra, M. Wouthuyzen-Bakker, A. Boonstra, H. de Jonge, M.M.M. Maerman, D.A. de Weerd, K.J. van Eije, M. Knoester, C.C. van Leer-Buter, H.G.M. Niesters, null T.Mudrikova, R.E. Barth, A.H.W. Bruns, P.M. Ellerbroek, M.P.M. Hensgens, J.J. Oosterheert, E.M. Schadd, A. Verbon, B.J. van Welzen, H. Berends, B.M.G. Griffioen-van Santen, I. de Kroon, F.M. Verduyn Lunel, A.M.J. Wensing, S. Zaheri, A.C. Boyd, D.O. Bezemer, A.I. van Sighem, C. Smit, M.M.J. Hillebregt, T.J. Woudstra, T. Rutkens, D. Bergsma, N.M. Brétin, K.J. Lelivelt, L. van de Sande, K.M. Visser.S.T. van der Vliet, F. Paling, L.G.M. de Groot-Berndsen, M. van den Akker, R. Alexander, Y. Bakker, A. El Berkaoui, M. Bezemer-Goedhart, E.A. Djoechro, M. Groters, L.E. Koster, C.R.E. Lodewijk, E.G.A. Lucas, L. Munjishvili, B.M. Peeck, C.M.J. Ree, R. Regtop, A.F. van Rijk, Y.M.C. Ruijs-Tiggelman, P.P. Schnörr, M.J.C. Schoorl, E.M. Tuijn, D.P. Veenenberg, E.C.M. Witte, I. Karpov, M. Losso, J. Lundgren, J. Rockstroh, I. Aho, L.D. Rasmussen, P. Novak, C. Pradier, N. Chkhartishvili, R. Matulionyte, C. Oprea, J.D. Kowalska, J. Begovac, J.M. Miró, G. Guaraldi, R. Paredes, L. Peters, J.F. Larsen, B. Neesgaard, N. Jaschinski, O. Fursa, D. Raben, D. Kristensen, A.H. Fischer, S.K. Jensen, T.W. Elsing, M. Gardizi, A. Mocroft, A. Phillips, J. Reekie, A. Cozzi-Lepri, A. Pelchen-Matthews, A. Roen, E.S. Tusch, W. Bannister, P. Bellecave, P. Blanco, F. Bonnet, S. Bouchet, D. Breilh, C. Cazanave, S. Desjardin, V. Gaborieau, A. Gimbert, M. Hessamfar, L. Lacaze-Buzy, D. Lacoste, M.E. Lafon, E. Lazaro, O. Leleux, F. Le Marec, G. Le Moal, D. Malvy, L. Marchand, P. Mercié, D. Neau, I. Pellegrin, A. Perrier, V. Petrov-Sanchez, M.O. Vareil, L. Wittkop, N. Bernard, D. Bronnimann H. Chaussade, D. Dondia, P. Duffau, I. Faure, P. Morlat, E. Mériglier, F. Paccalin, E. Riebero, C. Rivoisy, M.A. Vandenhende, L. Barthod, F.A. Dauchy, A. Desclaux, M. Ducours, H. Dutronc, A. Duvignaud, J. Leitao, M. Lescure, D. Nguyen, T. Pistone, M. Puges, G. Wirth, C. Courtault, F. Camou, C. Greib, J.L. Pellegrin, E. Rivière, J.F. Viallard, Y. Imbert, M. Thierry-Mieg, P. Rispal, O. Caubet, H. Ferrand, S. Tchamgoué, S. Farbos, H. Wille, K. Andre, L. Caunegre, Y. Gerard, F. Osorio-Perez, I. Chossat, G. Iles, M. Labasse-Depis, F. Lacassin, A. Barret, B. Castan, J. Koffi, N. Rouanes, A. Saunier, J.B. Zabbe, G. Dumondin, G. Beraud, M. Catroux, M. Garcia, V. Giraud, J.P. Martellosio, F. Roblot, T. Pasdeloup, A. Riché, M. Grosset, S. Males, C. Ngo Bell, C. Carpentier, Virology P. Bellecave, C. Tumiotto, G. Miremeont-Salamé, D. Arma, G. Arnou, M.J. Blaizeau, P. Camps, M. Decoin, S. Delveaux, F. Diarra, L. Gabrea, S. Lawson-Ayayi, E. Lenaud, D. Plainchamps, A. Pougetoux, B. Uwamaliya, K. Zara, V. Conte, M. Gapillout, Internal medicine, VU University medical center, Medical Microbiology and Infection Prevention, AII - Infectious diseases, CCA - Cancer biology and immunology, AII - Inflammatory diseases, AMS - Rehabilitation & Development, APH - Quality of Care, Pulmonary medicine, ACS - Pulmonary hypertension & thrombosis, Ethics, Law & Medical humanities, APH - Methodology, Midwifery Science, Amsterdam Reproduction & Development (AR&D), Infectious diseases, APH - Digital Health, APH - Personalized Medicine, APH - Aging & Later Life, APH - Global Health, Global Health, APH - Health Behaviors & Chronic Diseases, Center of Experimental and Molecular Medicine, General Internal Medicine, AII - Cancer immunology, Landsteiner Laboratory, Cardiology, ACS - Heart failure & arrhythmias, Obstetrics and Gynaecology, ARD - Amsterdam Reproduction and Development, Microbes in Health and Disease (MHD), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Global Health in the Global South (GHiGS), Institut de Recherche pour le Développement (IRD)- Bordeaux population health (BPH), and Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
Hepatitis B virus ,model validation ,Hepatology ,liver neoplasms ,risk prediction models ,liver cirrhosis ,lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4] ,risk assessment ,610 Medicine & health ,hepatocellular carcinoma ,HIV infection ,tenofovir ,lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4] ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,610 Medizin und Gesundheit - Abstract
Background & Aims: HBV coinfection is common among people living with HIV (PLWH) and is the most important cause of hepatocellular carcinoma (HCC). While risk prediction tools for HCC have been validated in patients with HBV monoinfection, they have not been evaluated in PLWH. Thus, we performed an external validation of PAGE-B in people with HIV/HBV coinfection.Methods: We included data on PLWH from four European cohorts who were positive for HBsAg and did not have HCC before starting tenofovir. We estimated the predictive performance of PAGE-B for HCC occurrence over 15 years in patients receiving tenofovir-containing antiretroviral therapy. Model discrimination was assessed after multiple imputation using Cox regression with the prognostic index as a covariate, and by calculating Harrell's c-index. Calibration was assessed by comparing our cumulative incidence with the PAGE-B derivation study using Kaplan-Meier curves.Results: In total, 2,963 individuals with HIV/HBV coinfection on tenofovir-containing antiretroviral therapy were included. PAGE-B was Conclusions: For individuals with HIV/HBV coinfection, PAGE-B is a valid tool to determine the need for HCC screening. Impact and implications: Chronic HBV infection is the most important cause of hepatocellular carcinoma (HCC) among people living with HIV. Valid risk prediction may enable better targeting of HCC screening efforts to high-risk individuals. We aimed to validate PAGE-B, a risk prediction tool that is based on age, sex, and platelets, in 2,963 individuals with HIV/HBV coinfection who received tenofovir-containing antiretroviral therapy. In the present study, PAGE-B showed good discrimination, adequate calibration, and a cut-off of
- Published
- 2023
- Full Text
- View/download PDF
3. Intérêt diagnostique de la TEP-TDM au 18F-FDG dans le diagnostic d’endocardite infectieuse sur valve native
- Author
-
V. Prega-Renaud, M. Dijos, E. Hindie, L. Bordenave, F. Camou, and G. Tlili
- Subjects
Radiological and Ultrasound Technology ,Biophysics ,Radiology, Nuclear Medicine and imaging - Published
- 2022
- Full Text
- View/download PDF
4. Pronostic des endocardites infectieuses chez les sujets âgés de 80 ans et plus de 2013 à 2020
- Author
-
V. Hémar, F. Camou, C. Roubaud-Baudron, J. Ternacle, M. Pernot, C. Greib, H. Chaussade, O. Peuchant, F. Bonnet, and N. Issa
- Published
- 2023
- Full Text
- View/download PDF
5. Infectious aortitis mimicking Takayasu disease
- Author
-
N. Issa, J. Constans, F. Camou, C. Carcaud, and Guillaume Vial
- Subjects
medicine.medical_specialty ,Fatal outcome ,business.industry ,Predictive value of tests ,Internal medicine ,Disease progression ,medicine ,Cardiology and Cardiovascular Medicine ,medicine.disease ,Takayasu Disease ,business ,Delayed diagnosis ,Aortitis - Published
- 2020
- Full Text
- View/download PDF
6. Nouvelles recommandations de l’ESC sur la prise en charge de l’endocardite : quelles nouveautés pour le chirurgien ?
- Author
-
G. Tlili, Marina Dijos, Claire Cornolle, Stephane Lafitte, Laurent Barandon, F. Camou, and M. Pernot
- Subjects
03 medical and health sciences ,0302 clinical medicine ,business.industry ,Medicine ,030212 general & internal medicine ,030204 cardiovascular system & hematology ,Cardiology and Cardiovascular Medicine ,business - Published
- 2018
- Full Text
- View/download PDF
7. Traitement des infections de prothèse vasculaire
- Author
-
Jocelyne Caillon, Frédéric Laurent, L. Legout, F. Camou, O. Leroy, and J. Sobocinski
- Subjects
0301 basic medicine ,03 medical and health sciences ,0302 clinical medicine ,030106 microbiology ,Emergency Medicine ,030212 general & internal medicine ,Emergency Nursing - Abstract
Les infections de prothese vasculaire necessitent une prise en charge medicochirurgicale. Une antibiotherapie probabiliste pourra etre instauree avant le traitement chirurgical en cas de sepsis severe, de choc septique ou de menace de complications mecaniques septiques (desunion anastomotique, rupture anevrismale). Elle repose sur une association d’un glycopeptide, d’une betalactamine a large spectre et d’un aminoside. Une fois la ou les bacterie(s) causale(s) identifiee(s) par les hemocultures et/ou les prelevements peroperatoires et les donnees d’antibiogramme connues, une antibiotherapie specifique a spectre le plus etroit possible sera prescrite pour une duree totale de six semaines postoperatoires. En cas de traitement chirurgical non optimal, une antibiotherapie suppressive sera instauree dans les suites du traitement antibiotique usuel. La gestion chirurgicale de ces patients presentant une telle infection est complexe. Elle depend du mode de contamination de la prothese, du germe incrimine, de la localisation de la prothese infectee et de l’etat general du patient.
- Published
- 2016
- Full Text
- View/download PDF
8. Caractérisation de l’insuffisance rénale aiguë chez les patients de réanimation atteints du COVID-19
- Author
-
A. Dewitte, Sébastien Rubin, C. Carrié, Claire Rigothier, A. Boyer, A. Orieux, Christian Combe, F. Camou, D. Gruson, and R. Prevel
- Subjects
Gynecology ,medicine.medical_specialty ,2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,Nephrology ,business.industry ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,medicine ,CO-Co 04 ,business - Abstract
Introduction La frequence, la severite et la caracterisation de l’insuffisance renale aigue (l’IRA) n’avaient pas ete decrites dans les formes les plus severes de la maladie. Description Nous avons conduit une etude de cohorte observationnelle dans 4 services de reanimation du CHU de Bordeaux du 3 mars au 14 avril 2020. Tous les patients diagnostiques positifs au COVID-19 et presentant des signes de gravite respiratoire (besoin de ≥ 4 L/min d’oxygene pour maintenir une SpO2 ≥ 94 %) ont ete inclus. Methodes L’IRA etait definie selon les criteres KDIGO (creatinine + diurese). Une analyse urinaire systematique (incluant ionogramme urinaire, proteinurie et recherche de glycosurie, leucocyturie et hematurie) a ete realisee le jour de l’apparition de l’IRA. Une IRA transitoire a ete definie comme un retour a la creatininemie basale ou une baisse de plus de 50 % de la creatininemie dans les 72 heures apres le diagnostic d’IRA. Resultats Trois cent quatre-vingt patients positifs au COVID-19 ont ete admis au CHU de Bordeaux. Parmi eux, 45 (12 %) ont ete admis en reanimation auxquels s’ajoutent 26 patients transferes d’autres regions de France. Sur les 71 patients inclus, une IRA a ete diagnostiquee chez 57 (80 %) dont 20/57 patients avec une IRA stade 1, 20/57 stade 2 et 17/57 stade 3. Le suivi median etait de 17 [12–23] jours. Deux patients sont decedes dans les 72 h et une IRA transitoire etait presente chez 4/55 (7 %) patients. Les parametres de l’ionogramme urinaire n’etaient pas differents entre les patients ayant une IRA transitoire ou non. L’epuration extrarenale a ete necessaire chez 10 patients. Le rapport proteinurie/creatininurie etait de 82 [54–140] mg/mmol avec un ratio albuminurie/proteinurie a 0,23 ± 20. Une glycosurie a ete retrouvee chez 2 patients. Conclusion L’IRA associee aux formes severes de COVID-19 est tres frequente, persistante, severe et se presente sous la forme d’une atteinte tubulaire ou tubulo-interstitielle sans glycosurie.
- Published
- 2020
9. PF286 EARLY ADMISSION IN INTENSIVE CARE UNIT IS ASSOCIATED WITH LOWER MORBIDITY AND MORTALITY IN ACUTE MYELOID LEUKEMIA WITH HYPERLEUKOCYTOSIS: A RETROSPECTIVE ANALYSIS
- Author
-
Noel Milpied, N. Mottal, T. Cazaubiel, M. Sauvezie, P.-Y. Dumas, Thibaut Leguay, Nahema Issa, O. Guisset, F. Camou, F.-X. Gros, A. Pigneux, and G. Mourissoux
- Subjects
medicine.medical_specialty ,business.industry ,law ,Emergency medicine ,Retrospective analysis ,Medicine ,Myeloid leukemia ,Hematology ,business ,Intensive care unit ,Early admission ,law.invention - Published
- 2019
- Full Text
- View/download PDF
10. Usefulness of pneumococcal antigen urinary testing in the intensive care unit?
- Author
-
Naoum P. Issa, F. Camou, O. Guisset, E. Bessede, and G. Mourissoux
- Subjects
Adult ,Male ,medicine.medical_specialty ,Urinary system ,Bacteremia ,Unnecessary Procedures ,Sensitivity and Specificity ,Pneumococcal Infections ,law.invention ,Pulmonary Disease, Chronic Obstructive ,Young Adult ,law ,Drug Resistance, Multiple, Bacterial ,Internal medicine ,Lower respiratory tract infection ,Case fatality rate ,medicine ,Humans ,Hospital Mortality ,Intensive care medicine ,Aged ,Retrospective Studies ,Aged, 80 and over ,Antigens, Bacterial ,Cross Infection ,Diagnostic Tests, Routine ,business.industry ,Incidence ,Sputum ,Retrospective cohort study ,Middle Aged ,Pneumonia, Pneumococcal ,medicine.disease ,Intensive care unit ,Anti-Bacterial Agents ,Community-Acquired Infections ,Intensive Care Units ,Pneumococcal infections ,Streptococcus pneumoniae ,Infectious Diseases ,Female ,France ,medicine.symptom ,business - Abstract
Objectives The use of pneumococcal antigen urinary tests is substantially increasing and is associated with a significant cost. The relevant use of this test in the intensive care unit (ICU) should be better defined. Our aim was to define the role of this test in relation to other microbiological tests. We described a series of patients admitted to the ICU for an invasive pneumococcal disease (IPD). Patients and methods We conducted a retrospective and descriptive study of the microbiological tests used to diagnose IPD in patients admitted to the ICU of the University Hospital in Bordeaux. Our aim was to measure the sensitivity of these bacteriological tests and of the BinaxNOW® S. pneumoniae test. Results Between 2009 and 2013, 148 patients were admitted for an IPD. A lower respiratory tract infection was diagnosed in 96.6% of them (143 patients). The overall ICU case fatality rate was 17.6%. The sensitivity of the pneumococcal antigen urinary test, sputum bacteriological examination, and blood cultures was respectively 83%, 37.6%, and 29.7%. S. pneumoniae was isolated from at least one bacteriological sample in 48.6% of patients, but in 51.4%, the diagnosis was only based on the results of the pneumococcal antigen urinary test. Conclusion We suggest performing a pneumococcal antigen urinary test when an IPD is suspected, only if the bacteriological tests are still negative after 48 hours. This strategy would result in a substantial cost saving. Patients would not face any additional risks as the result of the pneumococcal antigen urinary test does not have any impact on the initially prescribed antibiotic therapy.
- Published
- 2015
- Full Text
- View/download PDF
11. Encéphalopathie hyperammoniémique révélant une récidive de myélome
- Author
-
B Blondeau, F Camou, S Dimicoli-Salazar, Nahema Issa, Philippe Morlat, and G Marit
- Subjects
Gynecology ,03 medical and health sciences ,medicine.medical_specialty ,0302 clinical medicine ,business.industry ,030220 oncology & carcinogenesis ,Gastroenterology ,Internal Medicine ,Medicine ,Hyperammonemic encephalopathy ,business ,030215 immunology - Abstract
Resume Introduction L’hyperammoniemie attribuee au myelome est rarement decrite. Observation Nous rapportons l’observation d’un patient de 63 ans admis en reanimation medicale pour confusion et troubles de la conscience en rapport avec une hyperammoniemie attribuee a une recidive de son myelome. La chimiotherapie permettait la diminution de l’ammoniemie et le retour a un etat de conscience normal. Conclusion L’encephalopathie hyperammoniemique est une complication rare du myelome, associee a un fort taux de mortalite. A notre connaissance, il s’agit du premier cas de recidive de myelome diagnostique et traite en reanimation.
- Published
- 2016
- Full Text
- View/download PDF
12. Patients de 80ans et plus hospitalisés en réanimation médicale et aux soins continus : étude prospective sur 10mois
- Author
-
F. Camou, C. Gabinski, O. Guisset, G. Mourissoux, C. Kernaleguen, and A. Reix
- Subjects
Gynecology ,medicine.medical_specialty ,business.industry ,Medical intensive care unit ,Emergency Medicine ,Medicine ,Elderly people ,Critical Care and Intensive Care Medicine ,business - Abstract
Resume Introduction Le vieillissement de la population a entraine une augmentation du nombre de patients de 80 ans et plus admis en reanimation et aux soins continus. L’objectif de cette etude est d’analyser les caracteristiques de ces patients âges, ainsi que leur devenir en termes de mortalite et d’autonomie a trois mois. Materiel et methode Tous les patients de 80 ans et plus hospitalises dans les services de reanimation medicale et de soins continus a l’hopital Saint-Andre (CHU de Bordeaux) sur une periode de dix mois ont ete inclus. Les caracteristiques suivantes ont ete relevees : lieu de vie, comorbidites, autonomie, diagnostic d’admission, score IGS2, moyens entrepris, prise de decision de limitation ou arret therapeutique. De meme, leur devenir en termes de mortalite et d’autonomie a ete reevalue a trois mois. Resultats Cent un patients de 80 ans et plus ont ete inclus durant cette periode. Avant l’hospitalisation, 91,5 % d’entre eux avaient une autonomie conservee et vivaient a domicile. Le diagnostic d’admission le plus frequent etait l’insuffisance respiratoire aigue ; 26 % des patients ont ete intubes, une decision de limitation therapeutique a ete prise pour 55 % de ces patients et 24 % sont decedes en reanimation. A trois mois, 13 % des survivants sont decedes. Conclusion Ces resultats confirment que les patients âges admis en reanimation sont autonomes et ont peu de comorbidites, refletant une selection des patients avant leur admission. Ils restent peu dependants a trois mois et vivent pour la tres grande majorite toujours a domicile. Ces resultats encouragent a poursuivre l’admission des patients de 80 ans et plus en reanimation.
- Published
- 2014
- Full Text
- View/download PDF
13. Leptospirose et thrombopénie
- Author
-
G. Mourissoux, O. Guisset, C. Gabinski, Nahema Issa, and F. Camou
- Subjects
Gynecology ,medicine.medical_specialty ,business.industry ,Gastroenterology ,Internal Medicine ,medicine ,business - Abstract
Resume Introduction La leptospirose est une anthropozoonose due a un spirochete, Leptospira interrogans , dont l’expression clinique est polymorphe. La thrombopenie est un signe biologique classique a la phase aigue de l’infection, dont le mecanisme de survenue est mal connu. Observation Nous rapportons l’observation d’un homme de 56 ans, hospitalise pour sepsis severe associe a une insuffisance renale aigue et une insuffisance hepatocellulaire. Compte tenu de la recente inondation de sa maison, le diagnostic de leptospirose etait rapidement pose. Un myelogramme etait realise en raison d’une thrombopenie a 9 G/L associee a une hyperferritinemie et une hypertriglyceridemie. Il mettait en evidence de nombreux megacaryocytes et des images d’hemophagocytose confirmant le diagnostic de syndrome d’activation macrophagique. Les anomalies biologiques se corrigeaient parallelement a la guerison de l’infection. Conclusion Nous suggerons que la destruction centrale des precurseurs par hemophagocytose est un mecanisme possible de la thrombopenie lors de la leptospirose dont le diagnostic repose sur la realisation d’un myelogramme.
- Published
- 2015
- Full Text
- View/download PDF
14. Le dosage plasmatique de Neutrophil Gelatinase-Associated Lipocalin (NGAL) prédit la défaillance rénale au cours du choc septique dès l’admission en réanimation
- Author
-
T. Lalanne, H. Pouyes, G. Mourissoux, C. Gabinski, S. Oger, Christian Paroissin, O. Guisset, E. Guilhon, F. Camou, Laboratoire de Mathématiques et de leurs Applications [Pau] (LMAP), and Université de Pau et des Pays de l'Adour (UPPA)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
Gynecology ,medicine.medical_specialty ,business.industry ,education ,030232 urology & nephrology ,General Medicine ,030204 cardiovascular system & hematology ,musculoskeletal system ,ComputingMethodologies_ARTIFICIALINTELLIGENCE ,3. Good health ,[MATH.MATH-PR]Mathematics [math]/Probability [math.PR] ,Neutrophil gelatinase-associated lipocalin ,03 medical and health sciences ,Disease susceptibility ,surgical procedures, operative ,0302 clinical medicine ,Anesthesiology and Pain Medicine ,TheoryofComputation_LOGICSANDMEANINGSOFPROGRAMS ,medicine ,Proto-Oncogene Proteins ,Rifle ,business ,human activities ,ComputingMilieux_MISCELLANEOUS ,health care economics and organizations - Abstract
Resume Introduction La defaillance renale au cours du choc septique est frequente, mais de diagnostic difficile faute de biomarqueur specifique. La Neutrophil Gelatinase-Associated Lipocalin plasmatique (pNGAL) est un biomarqueur a evaluer dans ce domaine. Patients et methodes Cinquante patients admis consecutivement dans un service de reanimation medicale pour choc septique ont ete inclus dans cette etude. Le diagnostic d’insuffisance renale aigue (IRA) etait retenu selon les criteres RIFLE et AKIN. L’objectif principal etait d’evaluer l’apport diagnostique du dosage de pNGAL realise dans le service a l’admission (D0), a 24 heures (D1) et a 48 heures (D2). Resultats Parmi les 50 patients inclus, 86 % ont presente une agression renale aigue, 48 % ont developpe une IRA persistante organique et 30 % ont beneficie d’une epuration extrarenale (EER). Des D0, pNGAL etait significativement plus eleve (471 ng/mL versus 134 ng/mL) chez les patients avec alteration de la fonction renale comparativement aux autres ( p Conclusion Au cours du choc septique, l’elevation de pNGAL est plus importante quand il existe une defaillance renale et que celle-ci est organique. Le dosage, des l’admission, de pNGAL pourrait, de ce fait, participer a la decision de recours ou non a une EER.
- Published
- 2013
- Full Text
- View/download PDF
15. Lymphome de Burkitt révélé par un « hyperwarburgisme »
- Author
-
T. Leguay, N. Issa, J. Victor, and F. Camou
- Subjects
Gynecology ,medicine.medical_specialty ,business.industry ,Anesthesiology ,Emergency Medicine ,medicine ,Emergency Nursing ,business - Published
- 2016
- Full Text
- View/download PDF
16. Réunion de concertation multidisciplinaire dans l’endocardite, exemple du CHU de Bordeaux
- Author
-
F. Camou and N. Issa
- Subjects
03 medical and health sciences ,0302 clinical medicine ,business.industry ,Medicine ,030212 general & internal medicine ,030204 cardiovascular system & hematology ,Cardiology and Cardiovascular Medicine ,business - Published
- 2018
- Full Text
- View/download PDF
17. L’endocardite infectieuse sur sondes de stimulateurs cardiaques
- Author
-
F. Camou, Raymond Roudaut, E. Jan, Philippe Ritter, and Pierre Bordachar
- Subjects
business.industry ,Medicine ,Cardiology and Cardiovascular Medicine ,business - Published
- 2010
- Full Text
- View/download PDF
18. Dermatomyosite à anticorps anti-MDA5 et pneumocystose : une association d’une particulière gravité
- Author
-
G. Mourrissoux, F. Camou, G. Baulier, Nahema Issa, and O. Guisset
- Subjects
030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Gastroenterology ,Internal Medicine ,030204 cardiovascular system & hematology - Abstract
Introduction Les dermatomyosites sont des pathologies a haut risque de pneumocystose parmi les maladies auto-immunes [1] . Nous rapportons ici le cas d’une pneumocystose developpee chez une patiente avec une authentique dermatomyosite a anticorps anti-MDA5. Observation Une femme de 57 ans est admise en reanimation pour un tableau de detresse respiratoire d’installation subaigue. Depuis 6 semaines elle est traitee par prednisone (1 mg/kg, 80 mg/jour) et azathioprine (100 mg/jour) pour un tableau de dermatomyosite avec anticorps anti-MDA5. Des le diagnostic elle presente un tableau de myalgies, atteinte cutanee (papules de Gottron), et atteinte pulmonaire interstitielle sans retentissement sur les EFR (DLCO non faite). Elle n’a pas d’autre antecedent significatif. Apres une amelioration clinique rapide, la patiente presente apres un mois de traitement une toux avec dyspnee. Les images interstitielles se majorent. Des IGIV (2 g/kg) sont ajoutees au traitement et la patiente est alors hospitalisee en medecine. Devant l’aggravation respiratoire, elle est transferee en reanimation. A son arrivee, la saturation est a 98 % sous 4 L/min, TA 130/90. Elle est subfebrile a 38°, les CPK sont a 2 N, la CRP a 122 mg/L. Les CD4 sont a 545/mm3, les lymphocytes totaux a 856/mm3. Les images interstitielles avec notamment de grandes plages de verre depoli se majorent nettement sur un nouveau scanner thoracique. La PCR Pneumocystis jiroveci sur ECBC est positive a 76 000 cp/mL avec un examen direct negatif, un LBA est realise et met en evidence une alveolite lymphocytaire (400 000 elts/mm3, 21 %) avec examen direct positif pour P. jiroveci. Un traitement par cotrimoxazole est rapidement debutee. La situation se degrade rapidement avec un tableau de SDRA puis de defaillance multiviscerale necessitant ventilation mecanique et epuration extrarenale. L’atteinte cutanee progresse avec de nouvelles lesions ainsi que l’atteinte musculaire avec une elevation des CPK. Malgre une majoration de la corticotherapie (3 bolus a 250 mg puis 2 mg/kg), la patiente decede. Discussion Les dermatomyosites a anticorps anti-MDA5 sont une entite recente dont l’atteinte pulmonaire est particulierement severe. Plusieurs cas de pneumocystose associees a une dermatomyosites a MDA5 ont deja ete rapportees et compliquees de deces [2] . La gravite de l’atteinte interstitielle, la corticotherapie generale et les perturbations du systeme immunitaire sont les facteurs de risque principaux de pneumocystose dans cette pathologie. Conclusion Une prophylaxie systematique par cotrimoxazole doit etre discutee dans le cas des dermatomyosites a anticorps anti-MDA5 et plus particulierement si une corticotherapie superieure a 20 mg/jour est instauree, meme si le taux de CD4 n’est pas abaisse.
- Published
- 2018
- Full Text
- View/download PDF
19. Bon usage des antibiotiques: étude prospective sur l'utilisation du linézolide dans un hôpital universitaire français
- Author
-
V. Duhalde, F. Camou, B. Lahille, J.-P. Pometan, and S. Pédeboscq
- Subjects
Gynecology ,medicine.medical_specialty ,business.industry ,Medicine ,General Medicine ,Medical prescription ,business ,Antibacterial agent - Abstract
Resume But de l'etude Decrire l'utilisation en pratique clinique d'un nouvel antibiotique : le linezolide dans un hopital universitaire francais, dans une population de patients tres eloignee de celle des etudes qui ont permis sa commercialisation. Patients et methodes Etude prospective, observationnelle, de cohorte realisee chez les patients traites par linezolide entre novembre 2005 et juin 2006 au sein des services de soin de l'hopital Saint-Andre (CHU de Bordeaux). Recueil des donnees suivantes : source de l'infection, germes isoles, terrain du patient, strategies d'antibiotherapie, durees de traitement et evolution des patients sous linezolide. Resultats Cinquante patients (reanimation, medecine interne) ont ete inclus. L'absence de recommandations locales sur le bon usage du linezolide a conduit a des prescriptions tres variees dans des infections recensees dans l'autorisation de mise sur le marche (AMM) : pneumonies nosocomiales et acquises sous ventilation mecanique (48 %), infections cutanees et des tissus mous (11 %). Mais egalement pour les infections hors AMM (41 %) : endocardites (7 %), infections intra-abdominales (13 %), infections osteoarticulaires (2 %), infection sur materiel (13 %) et fievre chez le neutropenique (6 %). La principale justification de l'utilisation du linezolide etait l'alteration de la fonction renale des patients (66 %), qui deconseillait l'utilisation des glycopeptides. Les germes isoles etaient principalement des staphylocoques. Conclusion Dans le cadre du bon usage des antibiotiques, il serait indique d'etablir des recommandations d'utilisation du linezolide au sein du guide d'antibiotherapie deja diffuse a l'hopital qui seraient un outil d'aide a la prescription, puis d'en reevaluer l'impact a l'occasion d'un nouvel observatoire des prescriptions.
- Published
- 2007
- Full Text
- View/download PDF
20. Improvement of Progressive Multifocal Leukoencephalopathy After Cidofovir Therapy in a Patient with a Destructive Polyarthritis
- Author
-
O. Caubet, J L Pellegrin, Estibaliz Lazaro, E. Ellie, H. Fleury, J F Viallard, F. Camou, S. Eimer, and M. E. Lafon
- Subjects
Microbiology (medical) ,Pathology ,medicine.medical_specialty ,viruses ,Central nervous system ,Organophosphonates ,JC virus ,Antibodies, Viral ,medicine.disease_cause ,Antiviral Agents ,Cytosine ,chemistry.chemical_compound ,Refractory ,Humans ,Medicine ,Aged ,business.industry ,Arthritis ,Progressive multifocal leukoencephalopathy ,Leukoencephalopathy, Progressive Multifocal ,Brain ,virus diseases ,General Medicine ,medicine.disease ,JC Virus ,Magnetic Resonance Imaging ,White matter changes ,Brain disease ,Radiography ,Treatment Outcome ,Infectious Diseases ,medicine.anatomical_structure ,chemistry ,Female ,Polyarthritis ,business ,Cidofovir - Abstract
The human neurotropic JC virus (JCV) is responsible for progressive multifocal leukoencephalopathy (PML), an infectious demyelinating brain disease with major morbidity and mortality, usually refractory to treatment. We describe a PML in a 67-year-old woman with a destructive polyarthritis associated with anti-JO1 antibodies treated with corticosteroids. Although glucocorticoid therapy was maintained, administration of cidofovir improved the neurological condition. Our observation demonstrates the expanding clinical importance of JCV in systemic rheumatic diseases, particularly when immunosuppressive agents are used, and neurological symptoms or white matter changes on central nervous system imaging should arouse the suspicion of PML.
- Published
- 2007
- Full Text
- View/download PDF
21. Endocardites à Pasteurella sp. Deux cas
- Author
-
Patrick Mercié, Jean-François Viallard, F. Camou, Sabine Pereyre, C. Gabinski, Jean-Luc Pellegrin, and O. Guisset
- Subjects
medicine.medical_specialty ,biology ,business.industry ,Mortality rate ,Pasteurellaceae ,biology.organism_classification ,medicine.disease ,Dermatology ,Surgery ,Pasteurella sp ,Infectious Diseases ,Infective endocarditis ,Medicine ,Endocarditis ,Pasteurella ,business ,Pasteurella multocida ,Pasteurellosis - Abstract
Human pasteurellosis is, in general, a locoregional infection due to contact with an animal. Systemic infections are rare and endocarditis is exceptionally described. The authors report two new cases of endocarditis due to Pasteurella spp, they then review 29 other published cases. Pasteurella spp. endocarditis presents as an acute form in 64% of cases and affects the aortic as often as the mitral valves. Contact with an animal is documented in 65% of cases. Pasteurella multocida is the most frequent species in this infection. The total death rate is 40% and can reach 57% of cases in case of immunodepression. The bad prognosis of this infection, justifies an early diagnosis and a rapid and adapted but not yet consensual medicosurgical treatment.
- Published
- 2005
- Full Text
- View/download PDF
22. Liens physiopathologiques entre maladie de Kikuchi et lupus : à propos de trois nouvelles observations
- Author
-
C. Leyral, F. Camou, O. Caubet, Jean-François Viallard, C. Perlemoine, and Jean-Luc Pellegrin
- Subjects
Gynecology ,medicine.medical_specialty ,Systemic disease ,Kikuchi-Fujimoto Disease ,Lupus erythematosus ,business.industry ,Gastroenterology ,Histiocytic necrotizing lymphadenitis ,medicine.disease ,Connective tissue disease ,Histiocytosis ,Internal Medicine ,medicine ,business - Abstract
Resume Introduction. – La lymphadenite histiocytaire necrosante ou maladie de Kikuchi-Fujimoto est une entite anatomoclinique rare, d'etiologie inconnue dont le diagnostic est evoque chez un adulte jeune, frequemment de sexe feminin, presentant des adenopathies le plus souvent cervicales, une fievre et une asthenie. La confirmation est apportee par l'etude histologique ganglionnaire. L'evolution est spontanement favorable, mais certains cas peuvent reveler ou evoluer vers un lupus cutane ou systemique. Exegese. – Nous rapportons trois nouvelles observations de maladie de Kikuchi : un cas simulant un lupus systemique, un second avec une eruption cutanee de type lupique, et un cas severe avec syndrome d'activation macrophagique dans le cadre d'une primo-infection EBV revelant un lupus erythemateux systemique. Conclusion. – La recherche d'une maladie lupique, imposant un suivi clinicobiologique de ces patients, est donc necessaire et nous discutons les possibles liens physiopathologiques unissant ces deux entites.
- Published
- 2005
- Full Text
- View/download PDF
23. Amylose primitive localisée à l'appareil urinaire. À propos de cinq cas
- Author
-
D. Fleury, G. Etienne, P. de Faucal, P. Duffau, P. Arlet, Y. Imbert, F. Camou, and M. Paccalin
- Subjects
Gynecology ,medicine.medical_specialty ,business.industry ,Gastroenterology ,Internal Medicine ,Medicine ,business - Abstract
Resume Propos. – Description clinique, radiologique, cystoscopique et evolutive de patients presentant une amylose primitive localisee a l'appareil urinaire. Methodes. – Nous avons repris, a partir d'un cas personnel et des observations du Registre francais des amyloses localisees, les cinq dossiers d'amylose primitive localisee ureterovesicale. Resultats. – Les cinq malades retenus sont trois hommes et deux femmes, d'âge moyen au diagnostic de 53 ans. Une hematurie macroscopique revelait la pathologie chez l'ensemble des patients, quatre patients presentaient des douleurs lombaires basses, une seule patiente alleguait des signes d'irritation vesicale. La presentation clinique et iconographique mimait une neoplasie, l'histologie redressant le diagnostic. La localisation de l'amylose primitive etait ureterovesicale dans trois cas, ureterale bilaterale dans deux cas et uniquement vesicale dans un cas. Une etude immunohistochimique etait pratiquee dans seulement deux cas, objectivant une amylose AL lambda. Des traitements varies etaient proposes. La recidive a quelques mois etait la principale complication suggerant la necessite d'un suivi regulier urographique et cystoscopique. Aucun patient ne presentait de myelome ou ne developpait d'amylose systemique. Conclusion. – L'amylose localisee a l'appareil urinaire est une affection rare, de presentation pseudotumorale dont le diagnostic est exclusivement histologique. Le mecanisme lesionnel n'est pas connu et le pronostic favorable. Il n'existe pas de traitement specifique, l'evolution est marquee par la frequence des recidives locoregionales. Au cours de la surveillance, des bilans d'extension repetes sont inutiles, en l'absence de survenue d'une amylose systemique ou d'une pathologie myelomateuse.
- Published
- 2005
- Full Text
- View/download PDF
24. Étude des PCR Pneumocystis jirovecii positives au CHU de Bordeaux : la prophylaxie ne peut pas être guidée par le taux de lymphocytes chez les patients de médecine interne
- Author
-
F. Camou, Pierre Duffau, Nahema Issa, F. Gabriel, and G. Baulier
- Subjects
0301 basic medicine ,03 medical and health sciences ,030106 microbiology ,Gastroenterology ,Internal Medicine - Abstract
Introduction L’epidemiologie de la pneumocystose (PCP) s’est modifiee ces dernieres annees et touche desormais preferentiellement des patients non infectes par le VIH et exposes a divers immunosuppresseurs (IS) [1] . Chez le sujet VIH, l’indication d’une prophylaxie medicamenteuse est bien codifiee [2] . Malheureusement, il n’existe pas de recommandations aussi claires dans d’autres contextes [3] . Nous avons voulu analyser le profil clinicobiologique des patients atteints de pathologies inflammatoires et auto-immunes (MAI) ayant une PCR Pneumocystis positive. Patients et methodes Notre etude retrospective porte sur des patients admis au CHU de Bordeaux entre janvier 2013 et janvier 2016 et ayant une qPCR ( quantitative polymerase chain reaction ) positive pour Pneumocystis jirovecii (PJ). Les patients ont ete classes retrospectivement en trois groupes : PCP certaine, possible et colonisation. Ces groupes ont ete constitues independamment des valeurs de PCR, a partir des donnees cliniques, du resultat de l’examen direct des secretions respiratoires, de l’imagerie et du traitement administre. Resultats Cent-cinquante patients avaient au moins une PCR PJ positive, dont 39 patients VIH, 35 avec une hemopathie maligne, 26 greffes d’organes, 10 cancers solides, 7 avec des pathologies diverses et 33 avec une MAI (groupe intitule « medecine interne »). Notre etude porte sur ce groupe « medecine interne ». Le ratio H/F etait de 1,54, l’âge moyen de 66 ans . Six colonisations, 15 PCP certaines, et 12 PCP possibles etaient identifiees. Les pathologies sous-jacentes etaient respectivement : polyarthrite rhumatoide ( n = 7 dont 2 avec vascularite), dermato/polymyosite ( n = 4), vascularites a ANCA ( n = 3), hepatite auto-immune ( n = 3), maladie de Horton/pseudopolyarthrite rhizomelique ( n = 3), cryoglobulinemie ( n = 3), pneumopathie interstitielle diffuse ( n = 2), nephropathie glomerulaire ( n = 2), anemie hemolytique auto-immune ( n = 1), hemophilie A acquise ( n = 1), spondylarthrite ankylosante( n = 1), sclerodermie ( n = 1), sarcoidose ( n = 1), myasthenie ( n = 1). Le delai moyen entre l’episode de PCP suspecte et le diagnostic de la MAI etait de 5,6 ans (0–28 ans). Une corticotherapie (CTC) etait prescrite chez 97 % des patients avant l’admission, depuis en moyenne 3,4 ans (19 jours–24 ans) a la dose quotidienne moyenne de 29,4 mg (5–80 mg). Une dose > 20 mg/jour etait retrouvee dans 64 % des cas. Neuf patients (27 %) recevaient une CTC seule sans autre IS associe. Vingt-trois patients (70 %) avaient recu en association a une CTC un traitement IS dans les 3 mois precedents (methotrexate : 21 %, azathioprine : 12 %, rituximab : 12 %, cyclophosphamide : 6 %, mycophenolate : 3 %, ciclosporine : 3 %). Un antecedent de traitement par rituximab etait note chez 21 % des patients avec un delai moyen par rapport a la derniere injection de 1 an (26 j–3 ans), et un nombre moyen d’injections de 4,5. Un patient avait recu un anti-TNF (etanercept) et un autre du tocilizumab mais ils avaient recu d’autres IS depuis. Aucun des patients n’avait d’antecedent de PCP, un seul patient recevait une prophylaxie (pentacarinat). Un taux de lymphocytes CD4 avait ete realise avant l’episode chez 30 % des patients et etait en moyenne de 709/mm 3 (61–2 459). Un taux de lymphocytes CD4 avait ete realise pendant l’episode chez 66 % des patients et etait en moyenne de 333/mm 3 (12–1 202). Il etait > 200/mm 3 dans plus de 70 % des cas. Le taux de lymphocytes totaux, disponible pour tous les patients, etait en moyenne de 946/mm 3 . Plus de 60 % des patients avaient un taux > 600/mm 3 . On denombrait 13 deces au decours immediat de l’episode (40 %) dont 7 directement attribuables a la PCP (21 %). Discussion La PCP chez les patients de medecine interne est une pathologie severe. Les delais de survenue par rapport au diagnostic de la MAI et le debut du traitement IS notamment le rituximab sont tres variables. Une corticotherapie est presque toujours retrouvee a des doses excedant souvent 20 mg/j. Les taux de CD4 et de lymphocytes totaux ne permettent pas de guider l’indication d’une prophylaxie dans le contexte particulier des MAI. Conclusion Une prophylaxie anti-PCP chez les patients de medecine interne doit etre discutee independamment du taux de lymphocytes et avant tout en fonction d’un risque individuel base sur le risque propre lie a la MAI, la presence d’une corticotherapie, et le type d’IS associe.
- Published
- 2016
- Full Text
- View/download PDF
25. Intérêt du rituximab dans la maladie des agglutinines froides
- Author
-
F. Camou, Jean-Luc Pellegrin, and Jean-François Viallard
- Subjects
Gynecology ,medicine.medical_specialty ,Anticorps monoclonal ,Cold agglutinin disease ,business.industry ,Gastroenterology ,Internal Medicine ,medicine ,Rituximab ,medicine.disease ,business ,medicine.drug - Abstract
Resume Propos. – La maladie des agglutinines froides est une anemie hemolytique auto-immune chronique liee a un syndrome lymphoproliferatif a potentiel degeneratif dont le traitement n’est pas codifie. Cette affection rare est liee a la production d’IgM anti-erythrocytaires. Elle est responsable de crises hemolytiques parfois severes et d’un acrosyndrome vasculaire lors de l’exposition au froid. Avant l’ere du rituximab, un anticorps monoclonal dirige contre l’antigene CD20 lymphocytaire B, aucun traitement n’avait fait preuve de son efficacite. Methode. – Nous rapportons une serie de 5 patients traites par 4 perfusions de rituximab puis nous effectuons une revue de la litterature concernant les 23 autres observations similaires publiees. Resultats. – Avec une bonne tolerance, le traitement a permis une remission dans tous les cas (4 partielles, 1 complete). Parmi les 23 observations publiees, le taux de reponse a ete de 21/23 (dont 14 remissions completes). Conclusion. – Le rituximab constitue une alternative au traitement de la maladie des agglutinines froides.
- Published
- 2003
- Full Text
- View/download PDF
26. [Hyperammonemic encephalopathy as the presenting feature of a relapsing multiple myeloma]
- Author
-
N, Issa, B, Blondeau, S, Dimicoli-Salazar, G, Marit, P, Morlat, and F, Camou
- Subjects
Male ,Brain Diseases ,Humans ,Hyperammonemia ,Middle Aged ,Neoplasm Recurrence, Local ,Multiple Myeloma - Abstract
Hyperammonemia attributed to multiple myeloma has been rarely reported.We report a 63-year-old man who was admitted to an intensive care unit for confusion and altered mental status progressing to coma that was related to a relapsing multiple myeloma. Chemotherapy allowed the reduction of serum ammonia and the return to a normal state of consciousness.Hyperammonemic encephalopathy is a rare complication of multiple myeloma and is associated with high in-patient mortality. To our knowledge, this is the first case of hyperammonemic encephalopathy due to a relapsing myeloma diagnosed and treated in intensive care unit.
- Published
- 2015
27. [Leptospirosis and thrombocytopenia]
- Author
-
N, Issa, O, Guisset, G, Mourissoux, C, Gabinski, and F, Camou
- Subjects
Male ,Humans ,Leptospirosis ,Middle Aged ,Thrombocytopenia - Abstract
Leptospirosis is a worldwide zoonosis caused by the spirochete Leptospira interrogans. The spectrum of symptoms reported in leptospirosis is extremely broad. Thrombocytopenia is common during the acute phase of leptospirosis but its pathophysiological mechanism remains not well defined.We report a 56-year-old man hospitalized for severe sepsis with acute kidney injury and liver failure. Because of the recent flood of his house, we suspected leptospirosis. The diagnosis was rapidly confirmed. Blood tests revealed thrombocytopenia at 9 G/L associated with hyperferritinemia and hypertriglyceridemia. Cytological examination of bone marrow showed abundance of megakaryocytes and hemophagocytosis which confirmed the diagnosis of hemophagocytic syndrome. Clinical symptoms resolved and blood tests returned to normal values in the same time.We suggest that hemophogocytosis is a possible mechanism of thrombocytopenia in leptospirosis and that examination of bone marrow should be performed to confirm the diagnosis.
- Published
- 2014
28. Infections liées à une chambre implantable chez des patients infectés par le VIH
- Author
-
C. Cazorla, Michel Dupon, Lacut Jy, M P Moiton, Hervé Dutronc, Jean-Marie Ragnaud, Didier Neau, and F. Camou
- Subjects
Gynecology ,medicine.medical_specialty ,Infectious Diseases ,business.industry ,medicine ,business - Abstract
Resume Objectifs Les infections de chambre implantable sont reputees plus frequentes chez les patients atteints de sida que chez d'autres patients. Nous avons voulu verifier ce constat. Materiel et methodes Nous rapportons une etude retrospective portant sur dix ans; 31 infections de chambre implantable ont ete retrouvees, concernant 22 patients differents, tous infectes par le VIH. Resultats Ces infections etaient diagnostiquees environ 170 jours apres la mise en place du materiel. Les bacteries responsables etaient: staphylocoque a coagulase negative (23 cas), S. aureus (cinq cas), Enterococcus faecalis (un cas), bacilles a Gram negatif (cinq cas), Candida albicans (un cas). Ces infections ont donne lieu dans 13 cas a des hemocultures positives a la fois par ponction peripherique et par ponction a travers le dispositif. Le traitement a ete efficace dans 22 cas, bien qu'il ait ete necessaire d'enlever le materiel dans six cas. Une rechute avec la meme bacterie a ete constatee trois fois, six patients sont decedes. Conclusion Notre etude montre la meme epidemiologie bacterienne que celle rapportee dans d'autres series publiees. Les facteurs de risque sont egalement identiques: degre d'immunodepression, duree d'hospitalisation, frequence d'utilisation du materiel. Enfin, si l'antibiotherapie est indispensable, l'ablation du materiel ne semble pas systematiquement necessaire.
- Published
- 1999
- Full Text
- View/download PDF
29. Un blaste peut en cacher un autre
- Author
-
G. Baulier, F. Camou, G. Mourissoux, B. Claire, Nahema Issa, and O. Guisset
- Subjects
Gastroenterology ,Internal Medicine - Abstract
Introduction Devant une hyperleucocytose majeure associee a des blastes circulants, le diagnostic le plus facilement evoque est celui de leucemie aigue mais des diagnostics differentiels sont a envisager. Observation Un patient de 55 ans etait adresse aux urgences pour une hyperleucocytose a plus de 500 000/mm3. Ce bilan avait ete realise dans un contexte d’asthenie evoluant depuis 3 semaines associee a une douleur permanente de l’hypochondre gauche. Il n’avait pas d’antecedent personnel ou familial. Sur la biologie initiale, la creatinine etait a 97 μmol/L, l’acide urique a 697 μmol/L, les LDH a 1519 UI/L ; temoin d’une lyse spontanee. L’hemoglobine etait a 10,5 g/dL, le VGM a 106, les plaquettes a 227 000/mm3, les leucocytes a 594 000/mm3 sans anomalie de la coagulation. Une volumineuse hepato-splenomegalie etait palpable a 4 travers de doigt, ainsi que des adenopathies inguinales inferieures a 2 cm, sans atteinte cutaneo-muqueuse. Il n’y avait pas d’argument pour une leucostase. Les frottis medullaire et sanguin en urgence mettaient en evidence une population heterogene de cellules plus ou moins immatures de taille variable, de haut rapport nucleo-cytoplasmique, a chromatine un peu lâche, et noyaux generalement ronds, mais parfois irreguliers, voire foliaces. Par ailleurs, on notait la presence de cellules avec une chromatine plus fine, nucleolee. Le cytoplasme etait basophile, non granuleux. Le test a la peroxydase sur sang et mœlle etait negatif. Les serologies etaient negatives. Un scanner thoraco-abdomino-pelvien permettait de visualiser une volumineuse hepato-splenomegalie. Il existait des hypodensites spleniques en faveur d’infarctus recents probablement responsable du tableau douloureux initial. Un diagnostic de lymphome du manteau de forme blastoide etait propose sur les aspects cytologiques et confirme par l’immunophenotypage sanguin et medullaire en faveur d’une hemopathie lymphoide B kappa CD5+/CD23–/CD20+/CD10–ainsi que sur la biopsie medullaire avec un infiltrat massif (80 %) CD20+/CD5+/CD3–/CD10–/CD23–avec Bcl2 et cycline D-1 positif. Une chimiotherapie par cyclophosphamide, vincristine et prednisone etait debutee avec une diminution rapide des cellules lymphomateuses circulantes, une autogreffe etait envisage apres chimiotherapie par rituximab, aracytine, carboplatine, dexamethasone. Discussion Les lymphomes du manteau sont une entite rare (7–9 % des lymphomes) survenant generalement chez des individus de plus de 60 ans avec une nette predominance masculine. La presentation est souvent d’emblee generalisee et agressive avec une polyadenopathie, une splenomegalie et une atteinte medullaire. Le pronostic reste sombre, lie principalement aux rechutes frequentes et aux stades avances au diagnostic [1] . Dans 20–30 % des cas, il existe des cellules lymphomateuses circulantes. Le phenotype est generalement celui d’une cellule B mature (CD5+ CD23–) avec une sur-expression de la cycline D1. Ce dernier element est caracteristique des lymphomes du manteau et resulte d’une translocation t(11 ; 14) (q13 ; q32) permettant la juxtaposition du gene codant pour les chaines lourdes d’immunoglobuline dans la region promotrice de la cycline D1, entrainant son expression constitutive et une deregulation du cycle cellulaire. Quatre formes sont distinguees au sein des lymphomes du manteau en fonction de l’aspect en cytologie [2] : la forme a petites cellules, la forme classique du manteau, la forme pleiomorphe, et la forme blastique ou blastoide. Cette derniere consideree comme la plus agressive et dont les cellules ressemblent a des lymphoblastes possedent une chromatine lâche et un index mitotique eleve. Cette forme peut donc etre confondue avec une leucemie aigue lymphobastique (LAL), ou une leucemie a prolymphocytes B. Conclusion La presentation blastique d’emblee et la tres haute cellularite contrastent malgre tout dans notre cas clinique avec un etat general moderement altere et surtout une absence de leucostase ainsi qu’une lyse spontanee modeste. La splenomegalie majeure initiale peut egalement faire evoquer des diagnostics alternatifs comme : une leucemie a tricholeucocytes (toutefois absence de monocytopenie dans notre cas), un lymphome splenique a lymphocytes villeux ou une leucemie lymphoide chronique. C’est l’immunophenotypage sanguin et medullaire qui a permis de poser avec certitude le diagnostic de lymphome du manteau de forme blastoide. L’interet de cette observation reside dans l’importance de l’hyperleucocytose pouvant egarer le diagnostic vers une leucemie aigue ; rares sont les cas rapportes de lymphome du manteau avec une hyperleucocytose aussi majeure (2 cas) [3] .
- Published
- 2015
- Full Text
- View/download PDF
30. [Plasma Neutrophil Gelatinase-Associated Lipocalin (NGAL) predicts acute kidney injury in septic shock at ICU admission]
- Author
-
F, Camou, S, Oger, C, Paroissin, E, Guilhon, O, Guisset, G, Mourissoux, H, Pouyes, T, Lalanne, and C, Gabinski
- Subjects
Adult ,Male ,Comorbidity ,Acute Kidney Injury ,Middle Aged ,Shock, Septic ,Lipocalins ,Diuresis ,Kidney Tubules, Proximal ,Renal Replacement Therapy ,Intensive Care Units ,Norepinephrine ,Lipocalin-2 ,Predictive Value of Tests ,Creatinine ,Proto-Oncogene Proteins ,Humans ,Female ,Disease Susceptibility ,Prospective Studies ,Biomarkers ,Acute-Phase Proteins ,Aged - Abstract
To validate plasma Neutrophil Gelatinase-Associated Lipocalin (pNGAL) as an early biomarker in intensive care unit (ICU) for acute kidney injury (AKI) in critically ill adult with septic shock.Fifty consecutive patients with septic shock were included in this observational cohort study. AKI was defined if patients met any RIFLE or AKIN criteria. The main objective was to evaluate diagnosis value of pNGAL measured with a point-of-care device at admission (D0), at 24hours (D1) and at 48hours (D2).Among the 50 patients enrolled, 86% had AKI, 48% had persistent renal AKI and 30% required renal replacement therapy (RRT) during their ICU stay. At D0, pNGAL concentration was significantly higher in patients with AKI compared to patients without AKI (471ng/mL versus 134ng/mL, P0.001). This level remained significantly higher in the AKI population at D1 and D2 and pNGAL concentration at D0 among AKI patients increased with kidney failure level. At D1, pNGAL was significantly higher for persistent renal AKI rather than transient prerenal (570ng/mL versus 337ng/mL, P=0.027). pNGAL concentration below 348ng/mL at D1 was never seen in patients with RRT.Plasma NGAL is a useful, sensitive and early biomarker to predict persistent AKI in septic shock at ICU admission and help to discuss RRT.
- Published
- 2012
31. Un test diagnostique rapide négatif n’exclut pas une angine streptococcique
- Author
-
G. Bonnet, N. Issa, F. Camou, and X. Demant
- Subjects
business.industry ,Emergency Medicine ,Medicine ,business - Published
- 2014
- Full Text
- View/download PDF
32. Recurrent subarachnoid hemorrhage associated with a new transthyretin variant (Gly53Glu)
- Author
-
C. Rummens, Sophie Valleix, Anne Vital, E. Ellie, M. Delpech, F. Camou, and G. Grateau
- Subjects
Adult ,Male ,medicine.medical_specialty ,Pathology ,Subarachnoid hemorrhage ,Amyloid ,Molecular Sequence Data ,Central nervous system disease ,Myelopathy ,Recurrence ,Internal medicine ,medicine ,Humans ,Prealbumin ,Dementia ,Base Sequence ,biology ,Vascular disease ,business.industry ,Amyloidosis ,Genetic Variation ,nutritional and metabolic diseases ,Middle Aged ,Subarachnoid Hemorrhage ,medicine.disease ,Transthyretin ,Endocrinology ,Amino Acid Substitution ,biology.protein ,Female ,Neurology (clinical) ,Tomography, X-Ray Computed ,business - Abstract
CNS involvement is rare in systemic amyloidoses due to transthyretin (TTR) mutation and manifests as a combination of dementia, seizures, and myelopathy. The authors report two French siblings who experienced recurrent subarachnoid hemorrhages as the main clinical feature. Brain specimens showed that the leptomeningeal vessels walls were thickened by amyloid deposits, and sequencing of the TTR exons showed a heterozygous single base-pair transition from G to A (codon 53), resulting in a glycine for glutamic acid substitution (G53E).
- Published
- 2001
- Full Text
- View/download PDF
33. [Proper use of antibiotics: a prospective study on the use of linezolid in a French university hospital]
- Author
-
V, Duhalde, B, Lahille, F, Camou, S, Pédeboscq, and J-P, Pometan
- Subjects
Cohort Studies ,Hospitals, University ,Clinical Trials as Topic ,Anti-Infective Agents ,Endocarditis ,Acetamides ,Linezolid ,Humans ,Bacterial Infections ,France ,Pneumonia ,Oxazolidinones ,Anti-Bacterial Agents - Abstract
To describe clinical use of a new antibiotic: linezolid, in a French university hospital, on a population of patients different from the one studied during the clinical trials for the marketing authorisation.An observational, prospective cohort study performed in patients treated by linezolid between November 2005 and June 2006 at Saint André hospital (Bordeaux University Hospital). The following data were collected: sources of infection, isolated pathogens, patient's background, antibiotherapy strategies, duration of therapy and evolution.Fifty patients (intensive care, internal medicine) were included. The absence of local guidelines on proper use of linezolid led to various prescriptions as well in infections listed in the marketing authorisation: nosocomial pneumonia and ventilator associated pneumonia (48%), skin and soft tissue infections (11%), as in endocarditis (7%), intra-abdominal infections (13%), bone and joint infections (2%), catheter infections (13%) and febrile neutropenic patients (6%). The main justification for using linezolid was worsening renal dysfunction (66%), which contra indicated glycopeptides use. Isolated pathogens were for the major part staphylococcus.In the context of proper use of antibiotics, it would be advisable to add new recommendations on the use of linezolid to the hospital's antibiotherapy guide which would constitute a tool for the prescribing clinicians, and to re-evaluate the impact during a second evaluation.
- Published
- 2007
34. [Endocarditis due to Pasteurella sp. Two cases]
- Author
-
F, Camou, O, Guisset, S, Pereyre, C, Gabinski, J-F, Viallard, P, Mercié, and J-L, Pellegrin
- Subjects
Aged, 80 and over ,Pasteurella Infections ,Humans ,Female ,Endocarditis, Bacterial ,Aged - Abstract
Human pasteurellosis is, in general, a locoregional infection due to contact with an animal. Systemic infections are rare and endocarditis is exceptionally described. The authors report two new cases of endocarditis due to Pasteurella spp, they then review 29 other published cases. Pasteurella spp. endocarditis presents as an acute form in 64% of cases and affects the aortic as often as the mitral valves. Contact with an animal is documented in 65% of cases. Pasteurella multocida is the most frequent species in this infection. The total death rate is 40% and can reach 57% of cases in case of immunodepression. The bad prognosis of this infection, justifies an early diagnosis and a rapid and adapted but not yet consensual medicosurgical treatment.
- Published
- 2005
35. [Pathogenic links between Kikuchi's disease and lupus: a report of three new cases]
- Author
-
C, Leyral, F, Camou, C, Perlemoine, O, Caubet, J L, Pellegrin, and J F, Viallard
- Subjects
Adult ,Diagnosis, Differential ,Male ,Humans ,Lupus Erythematosus, Systemic ,Female ,Histiocytic Necrotizing Lymphadenitis - Abstract
Histiocytic necrotizing lymphadenitis or Kikuchi-Fujimoto's disease is a rare anatomoclinical entity whose etiology remains unknown. It is mainly reported in young adult female, presenting with cervical lymphadenopathies, fever and asthenia. The diagnosis is based on the histological examination of a lymph node biopsy. The disease course is usually uneventful, but sometimes Kikuchi-Fujimoto's disease can reveal or evolve into a cutaneous or a systemic lupus.We report three new cases of Kikuchi's disease: the first one mimicked a systemic lupus, the second one was associated with a lupus-like rash, and a the last one was a severe case with hemophagocytic syndrome and a primo-infection with Epstein-Barr virus revealing a systemic lupus erythematosus.Clinical and biological follow-up of patients presenting with Kikuchi's disease is necessary to look for an association with a lupus. We discuss the pathogenic links between Kikuchi's disease and lupus.
- Published
- 2004
36. [Primary localized amyloidosis of the urinary tract. A case series of five patients]
- Author
-
P, Duffau, Y, Imbert, P, De Faucal, D, Fleury, P, Arlet, F, Camou, G, Etienne, and M, Paccalin
- Subjects
Adult ,Male ,Urinary Bladder Diseases ,Humans ,Ureteral Diseases ,Female ,Amyloidosis ,Middle Aged ,Aged - Abstract
To describe the clinical and radiographic features of patients with primary localized amyloidosis of the urinary tract.We report a case of localized amyloidosis of the ureters and bladder. The medical records of four other cases from the French Register of localized amyloidosis were reviewed.The mean age of three men and two women was 53 years. All patients presented with gross hematuria, four patients presented with renal colic, only one patient had irritative lower urinary tract symptoms. Ureter and bladder were involved in three patients, both ureters in two patients and the bladder only, in one patient. Clinical and radiographic presentations mimicked a neoplasia excluded by histologic analysis. Immunohistochemical study was performed in only two cases and revealed lambda light chain amyloidosis. The median follow-up was eight years. Various treatments were performed, and recurrences occurred in two cases. None of the five patients developed monoclonal gammapathy or systemic amyloidosis.Primary localized amyloidosis of the urinary tract is a rare disorder and can easily be confused with a neoplasm. The physiopathology is unknown, the prognosis is usually good. There is no specific treatment, and repeated work-up for systemic amyloidosis is unnecessary as local recurrences appear to be the main complication.
- Published
- 2004
37. [Rituximab in cold agglutinin disease]
- Author
-
F, Camou, J-F, Viallard, and J-L, Pellegrin
- Subjects
Male ,Antibodies, Monoclonal, Murine-Derived ,Treatment Outcome ,Immunoglobulin M ,Antibodies, Monoclonal ,Humans ,Antineoplastic Agents ,Female ,Anemia, Hemolytic, Autoimmune ,Middle Aged ,Rituximab ,Aged - Abstract
Cold agglutinin disease is a chronic auto-immune hemolytic anemia related to a lymphoproliferative disorder with a degenerative potential and no codified treatment. This rare affection is related to the production of anti-erythrocytes immunoglobulins M. They are responsible of hemolytic crises sometimes severe and vascular acrosyndrom when submitted to cold temperature. Before rituximab, a monoclonal antibody targeted against the B lymphocyte CD20 antigen, no treatment was really efficient.We present 5 patients who have been treated with 4 weekly rituximab perfusions, and then we proceed to a review of the literature concerning the other 23 similar cases.With a good tolerance, the treatment allowed a remission in all the cases (4 partial, 1 complete). Among the 23 observations published, the rate of answer was 21/23 (of which 14 gave completes).Rituximab is an alternative treatment of cold agglutinin disease.
- Published
- 2003
38. Les pneumonies à Staphylococcus aureus sécréteur de la leucocidine de Panton-Valentine
- Author
-
Frédéric Rivière, X. Roux, P. Imbert, Frédéric Méchaï, J.-L. Koeck, F Camou, B. Soullié, P Dubrous, and Christophe Rapp
- Subjects
business.industry ,Gastroenterology ,Internal Medicine ,Medicine ,business - Published
- 2010
- Full Text
- View/download PDF
39. Les vasculopathies cérébrales secondaires aux méningites bactériennes aiguës communautaires : à propos d’une série de 13 cas
- Author
-
C. Gabinski, F. Camou, M. Longy-Boursier, S. Molinier, Y. Castaing, M. Grenouillet-Delacre, E. Ribeiro, M. Griton, Didier Gruson, and O. Guisset
- Subjects
Gastroenterology ,Internal Medicine - Published
- 2011
- Full Text
- View/download PDF
40. Syndrome d'hypersensibilité et lupus induitpar la lamotrigine
- Author
-
G. Etienne, M.S. Dilhuydy, Patrick Mercié, F. Camou, M. Longy-Boursier, T. Carmoi, C. Gabinski, O. Guisset, and M. Grenouillet
- Subjects
Gastroenterology ,Internal Medicine - Published
- 2003
- Full Text
- View/download PDF
41. Le rituximab: Une alternative thérapeutiquedans la maladie des agglutinines froides
- Author
-
Jean-Luc Pellegrin, G. Etienne, F. Camou, M. Longy-Boursier, and Jean-François Viallard
- Subjects
Gastroenterology ,Internal Medicine - Published
- 2003
- Full Text
- View/download PDF
42. Efficacité des immunoglobulines intraveineuses dans la morphée généralisée
- Author
-
Claire Beylot, I. Noblesse, F. Camou, Marie-Sylvie Doutre, and Marie Beylot-Barry
- Subjects
Gastroenterology ,Internal Medicine - Published
- 2002
- Full Text
- View/download PDF
43. La maladie d'Erdheim-Chester
- Author
-
G. Etienne, F. Camou, M. Longy-Boursier, M. Lebras, and T. Carmoi
- Subjects
Gastroenterology ,Internal Medicine - Published
- 2002
- Full Text
- View/download PDF
44. Polynévrite des membres inférieurs révélant une périartérite noueuse chez un patient infecté par le VIH
- Author
-
A Vital, H Dutronc, F. Camou, M P Moiton, Jean-Marie Ragnaud, and Didier Neau
- Subjects
Gastroenterology ,Internal Medicine - Published
- 1997
- Full Text
- View/download PDF
45. Convalescent plasma in patients receiving rituximab or ocrelizumab for multiple sclerosis or neuromyelitis Optica spectrum disorder with Covid-19: A multicenter retrospective study.
- Author
-
Dequidt T, Richier Q, Louapre C, Ader F, Merad Y, Lauwerier N, Jacomet C, Carles M, Biron C, Gendrin V, Marlat C, Danion F, Lepage TM, Sotto A, Bourdellon L, Mania A, Martinot M, Falher GL, Ferre A, Pilmis B, Gondran G, Simeone P, Henry M, Kamel T, Ray S, Ancellin S, Mélé N, Camou F, Destremau M, Sellenet J, Zucman N, Le Maréchal M, Mellouki K, Langlois ME, Luque Paz D, Mousset M, Leclerc C, Sommet A, Lacombe K, and Martin-Blondel G
- Abstract
Background: Despite vaccination, patients receiving anti-CD20 monoclonal antibodies (mAbs) for multiple sclerosis (MS) or neuromyelitis optica spectrum disorders (NMOSD) have an increased risk of developing severe or protracted COVID-19. The aim of this study was to describe the effect of COVID-19 convalescent plasma (CCP) in patients with MS or NMOSD exposed to anti-CD20 and infected by SARS-CoV-2., Methods: This French national, retrospective cohort study was conducted between November 2020 and June 2023. Patients with MS or NMOSD, under anti-CD20 mAbs, with symptomatic COVID-19 and treated by CCP were screened. Protracted COVID-19 was defined by a duration of symptoms >21 days. The primary endpoint was the overall survival 30 days after CCP administration., Results: Ninety-two patients from 34 hospitals were included, 84 (91%) with MS and 8 (9%) with NMOSD. Overall, 30-day survival was 97% (IC95%: 91-99). SARS-CoV-2 viremia was positive in 47/75 (61%) patients before CCP versus 9/59 (15%) seven days post-CCP. In the 52 patients (57%) with protracted COVID-19, the duration of symptoms before CCP was 51 [28-69] days, including fever in 75% of cases, which disappeared in 100% of patients 7 days post-CCP., Conclusions: CCP could be a therapeutic option in patients exposed to anti-CD20 mAbs for inflammatory demyelinating disease, particularly in those with protracted COVID-19., Competing Interests: Declarations of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: KL has received funds from Gilead, MSD, Janssen, ViiV Healthcare and Abbvie for expert boards and travel grants. None of those funds target COVID-19. CL has received compensation for travel fees, consulting services or speaker honoraria from Biogen, Merck Serono, Novartis, Sanofi and Roche and IIT Research grant from Biogen. AF reports honorariat by Fisher & Paykel for a lecture during SFMU Congress 2022, outside the submitted work. AM is president of an association that has received funding from GSK and Blueprint, hospitality from GSK, Novartis, Sanofi, Janssen, Teva, Shire, Ipsen, training funding from Novartis, LFB, Leo Pharma, and has a contract to speak at scientific events from Leo Pharma. The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
46. Should We Reconsider Pneumocystis Pneumonia Presentation and Treatment According to Its Underlying Disease?: An Unsupervised Cluster Analysis of a Retrospective Multicenter Study.
- Author
-
Gaborit B, Lécuyer R, Issa N, Camou F, Lavergne RA, Gabriel F, Morio F, Canet E, Raffi F, Boutoille D, Cady A, Gousseff M, Crabol Y, Néel A, and Tessoulin B
- Subjects
- Humans, Retrospective Studies, Male, Female, Cluster Analysis, Middle Aged, Aged, Pneumonia, Pneumocystis diagnosis
- Abstract
Competing Interests: Financial/Nonfinancial Disclosures The authors have reported to CHEST the following: B. G. reports receipt of nonfinancial support from Gilead Sciences, MSD, and Pfizer outside the submitted work. F. R. reports receipt of personal fees from AbbVie, AstraZeneca, Gilead Sciences, Janssen, Merck, Roche, and ViiV Healthcare outside the submitted work. E. C. reports personal fees from GILEAD, SANOFI-GENZYME, and BAXTER outside the submitted work. B. T. reports receipt of nonfinancial support from Gilead Sciences and personal fees from AbbVie, Gilead Sciences, Lilly Oncology, and Incyte outside the submitted work. None declared (R. Lécuyer, N. I., F. C., R. Lavergne, F. G., F. M., D. B., A. C., M. G., Y. C., A. N.).
- Published
- 2024
- Full Text
- View/download PDF
47. Characteristics and Prognosis Factors of Pneumocystis jirovecii Pneumonia According to Underlying Disease: A Retrospective Multicenter Study.
- Author
-
Lécuyer R, Issa N, Camou F, Lavergne RA, Gabriel F, Morio F, Canet E, Raffi F, Boutoille D, Cady A, Gousseff M, Crabol Y, Néel A, Tessoulin B, and Gaborit B
- Subjects
- Humans, Male, Female, Retrospective Studies, Middle Aged, Prognosis, Aged, Immunocompromised Host, Risk Factors, Pneumonia, Pneumocystis diagnosis, Pneumonia, Pneumocystis epidemiology, Pneumonia, Pneumocystis mortality, Pneumocystis carinii isolation & purification
- Abstract
Background: Pneumocystis jirovecii pneumonia (PcP) remains associated with high rates of mortality, and the impact of immunocompromising underlying disease on the clinical presentation, severity, and mortality of PcP has not been adequately evaluated., Research Question: Does the underlying disease and immunosuppression causing PcP impact the outcome and clinical presentation of the disease?, Study Design and Methods: In this multicenter retrospective observational study, conducted from January 2011 to December 2021, all consecutive patients admitted with a proven or probable diagnosis of PcP according to the European Organisation for Research and Treatment of Cancer consensus definitions were included to assess the epidemiology and impact of underlying immunosuppressive diseases on overall and 90-day mortality., Results: Overall, 481 patients were included in the study; 180 (37.4%) were defined as proven PcP and 301 (62.6%) were defined as probable PcP. Patients with immune-mediated inflammatory diseases (IMIDs) or solid tumors had a statistically poorer prognosis than other patients with PcP at day 90. In multivariate analysis, among the HIV-negative population, solid tumor underlying disease (OR, 5.47; 95% CI, 2.16-14.1; P < .001), IMIDs (OR, 2.19; 95% CI, 1.05-4.60; P = .037), long-term corticosteroid exposure (OR, 2.07; 95% CI, 1.03-4.31; P = .045), cysts in sputum/BAL smears (OR, 1.92; 95% CI, 1.02-3.62; P = .043), and SOFA score at admission (OR, 1.58; 95% CI, 1.39-1.82; P < .001) were independently associated with 90-day mortality. Prior corticotherapy was the only immunosuppressant associated with 90-day mortality (OR, 1.67; 95% CI, 1.03-2.71; P = .035), especially for a prednisone daily dose ≥ 10 mg (OR, 1.80; 95% CI, 1.14-2.85; P = .010)., Interpretation: Among patients who were HIV-negative, long-term corticosteroid prior to PcP diagnosis was independently associated with increased 90-day mortality, specifically in patients with IMIDs. These results highlight both the needs for PcP prophylaxis in patients with IMIDs and to early consider PcP curative treatment in severe pneumonia among patients with IMIDs., Competing Interests: Financial/Nonfinancial Disclosures The authors have reported to CHEST the following: B. G. reports receipt of nonfinancial support from Gilead Sciences, MSD, and Pfizer, outside the submitted work. F. R. reports receipt of personal fees from Abbvie, Astra Zeneca, Gilead Sciences, Janssen, Merck, Roche, and ViiV Healthcare, outside the submitted work. E. C. reports personal fees from Gilead, Sanofi-Genzyme, and Baxter, outside the submitted work. None declared (R. L., N. I., F. C., R.-a. L., F. G., F. M., D. B., A. C., M. G., Y. C., A. N., B. T.)., (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
48. Convalescent plasma transfusion for immunocompromised viremic patients with COVID-19: A retrospective multicenter study.
- Author
-
Destremau M, Chaussade H, Hemar V, Beguet M, Bellecave P, Blanchard E, Barret A, Laboure G, Vasco-Moynet C, Lacassin F, Morisse E, Aguilar C, Lafarge X, Lafon ME, Bonnet F, Issa N, and Camou F
- Subjects
- Humans, Blood Component Transfusion, COVID-19 Serotherapy, Cohort Studies, Plasma, Immunocompromised Host, Viremia, COVID-19 therapy, Hematologic Neoplasms complications, Hematologic Neoplasms therapy
- Abstract
This study aims to assess the safety, virological, and clinical outcomes of convalescent plasma transfusion (CPT) in immunocompromised patients hospitalized for coronavirus disease 2019 (COVID-19). We conducted a retrospective multicenter cohort study that included all immunosuppressed patients with COVID-19 and RNAemia from May 2020 to March 2023 treated with CPT. We included 81 patients with hematological malignancies (HM), transplants, or autoimmune diseases (69% treated with anti-CD20). Sixty patients (74%) were vaccinated, and 14 had pre-CPT serology >264 BAU/mL. The median delay between symptom onset and CPT was 23 days [13-31]. At D7 post-CPT, plasma PCR was negative in 43/64 patients (67.2%), and serology became positive in 25/30 patients (82%). Post-CPT positive serology was associated with RNAemia negativity (p < 0.001). The overall mortality rate at D28 was 26%, being higher in patients with non-B-cell HM (62%) than with B-cell HM (25%) or with no HM (11%) (p = 0.02). Patients receiving anti-CD20 without chemotherapy had the lowest mortality rate (8%). Positive RNAemia at D7 was associated with mortality at D28 in univariate analysis (HR: 3.05 [1.14-8.19]). Eight patients had adverse events, two of which were severe but transient. Our findings suggest that CPT can abolish RNAemia and ameliorate the clinical course in immunocompromised patients with COVID-19., (© 2024 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF
49. The Mortality of Infective endocarditis with and without Surgery in Elderly (MoISE) Study.
- Author
-
Hémar V, Camou F, Roubaud-Baudron C, Ternacle J, Pernot M, Greib C, Dijos M, Wirth G, Chaussade H, Peuchant O, Bonnet F, and Issa N
- Subjects
- Aged, Male, Humans, Aged, 80 and over, Female, Prospective Studies, Retrospective Studies, Activities of Daily Living, Hospital Mortality, Endocarditis, Bacterial, Endocarditis surgery
- Abstract
Background: Infective endocarditis (IE) is increasingly affecting older patients. However, data on their management are sparse, and the benefits of surgery in this population are unclear., Methods: We included patients with left-sided IE (LSIE) aged ≥ 80 years enrolled in a prospective endocarditis cohort managed in Aquitaine, France, from 2013 to 2020. Geriatric data were collected retrospectively to identify factors associated with the 1-year risk of death using Cox regression., Results: We included 163 patients with LSIE (median age, 84 years; men, 59%; rate of prosthetic LSIE, 45%). Of the 105 (64%) patients with potential surgical indications, 38 (36%) underwent valve surgery: they were younger, more likely to be men with aortic involvement, and had a lower Charlson comorbidity index. Moreover, they had better functional status at admission (ie, the ability to walk unassisted and a higher median activities of daily living [ADL] score; n = 5/6 vs 3/6, P = .01). The 1-year mortality rate in LSIE patients without surgical indications was 28%; it was lower in those who were operated on compared with those who were not despite a surgical indication (16% vs 66%, P < .001). Impaired functional status at admission was strongly associated with mortality regardless of surgical status. In patients unable to walk unassisted or with an ADL score <4, there was no significant surgical benefit for 1-year mortality., Conclusions: Surgery improves the prognosis of older patients with LSIE and good functional status. Surgical futility should be discussed in patients with altered autonomy. The endocarditis team should include a geriatric specialist., Competing Interests: Potential conflicts of interest . F. B. reports research grants from Gilead and ViiV Healthcare and payments for educational events from Gilead, ViiV Healthcare, and MSD. The remaining authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2023
- Full Text
- View/download PDF
50. Patient reported outcomes of patients with Gaucher disease type 1 treated with eliglustat in real-world settings: The ELIPRO study.
- Author
-
Camou F, Lagadec A, Coutinho A, Berger MG, Cador-Rousseau B, Gaches F, and Belmatoug N
- Subjects
- Adult, Humans, Male, Middle Aged, Female, Quality of Life, Prospective Studies, Pain, Gaucher Disease drug therapy, Gaucher Disease diagnosis
- Abstract
Introduction: Gaucher disease type 1 (GD1) is a rare genetic lysosomal storage disorder. Eliglustat is a first-line oral therapy for adult patients with GD1. The aim of the ELIPRO (ELIglustat Patient Reported Outcomes) study was to assess real-world outcomes of eliglustat treatment for over 1 year in patients with GD1, with a focus on patient-reported outcomes (PROs), including treatment adherence., Methods: This was a non-interventional, prospective, multicentric study. Patients were stratified according to their previous time on eliglustat: >6 months (Group1) and ≤ 6 months (Group2). The primary endpoint was adherence to eliglustat, measured by the eight-items Morisky Medication Adherence Scale (MMAS-8; scale of 0-8) at 6 months in Group2. Secondary endpoints were quality of life (QoL) measured by patient input using the European Quality of Life five-dimensional three-level [EQ-5D-3L] questionnaire, fatigue and pain measured by numeric rating scale [NRS; on a scale of 0-10], the evaluation of patient satisfaction level regarding eliglustat treatment measured by Likert scale [scale of 0-7] and treatment adherence at 12 months in both groups. The study also evaluated the safety and effectiveness of eliglustat in the adult GD1 population., Results: Sixty patients with GD1 (approximatively 52% male, mean age: 46.6 ± 13.9 years) were analyzed: 29 in Group1 and 31 in Group2. GD1 was mostly of mild severity (90%) and 95% of patients had extensive CYP2D6 metabolizer phenotype. Fifty-seven patients had previously received treatment for GD1 (91% enzyme replacement therapy) and 15% were splenectomized. Groups1 and 2 were not necessarily matching for all characteristics. At 6 months, 58% of Group2 patients showed medium adherence (6 < MMAS-8 < 7.75) while 21% showed high adherence (MMAS-8: 8) (mean MMAS-8: 6.7 ± 1.0); similar results were obtained in Group1 (50% showed high compliance, 35% showed medium compliance; mean MMAS-8: 6.8 ± 1.4). The mean MMAS-8 for Group1 and Group2 were 7.1 ± 1.2 (vs 7.0 ± 1.0 at baseline) and 6.5 ± 1.0, respectively, at 12 months. At 12 months, the mean NRS scores in Group1 and Group2 were 72.0 ± 18.5 and 77.3 ± 13.7 for QoL (vs. 71.7 ± 18.4 and 80.2 ± 12.4, respectively at baseline), 4.8 ± 2.6 and 3.6 ± 2.7 for fatigue (vs. 4.6 ± 2.7 and 3.6 ± 2.6, respectively at baseline) and 3.3 ± 2.7 and 2.3 ± 2.3 for pain (vs. 3.3 ± 2.7 and 2.0 ± 2.4, respectively at baseline). GD1 assessments (biological, clinical and imaging parameters) remained stable during 12 months in both groups. At the end of the study, majority (97.4%) of patients were satisfied with their treatment with eliglustat (satisfaction score over 5 out of 7). Sixty-six percent of patients (n = 41) experienced mostly mild adverse events (AE) (including four study withdrawals), of whom 27.4% (n = 17) of patients experienced eliglustat-related AEs. Treatment adherence remained stable during 12 months in both groups., Conclusions: Eliglustat treatment compliance was good and sustained, along with overall health state, fatigue and pain levels, which was consistent with overall patients' clinical status. Eliglustat was well tolerated, and had a good safety profile, aligned with a good patient satisfaction. Our study should encourage greater use of PROs for evaluation of impact of the GD treatment on patient's symptoms and well-being., Competing Interests: Declaration of Competing Interest Fabrice CAMOU: consultancies with Sanofi, Takeda, AstraZeneca, Gilead, Pfizer; Scientific Advisory Boards for Sanofi, Pfizer. Angela COUTINHO: consultancies with Amicus Therapeutics, Orchard, Orphazyme and Sanofi. Marc G. BERGER: consultancies with Sanofi, Takeda, Pfizer, Novartis; Scientific Advisory Boards for Sanofi, Takeda, Pfizer, Novartis; GHI: research grants from Pfizer. Bérengère CADOR-ROUSSEAU: consultancies with Sanofi, Amicus, and Takeda. Francis GACHES: consultancies with Sanofi and Novartis; Scientific Advisory Boards for Sanofi. Nadia BELMATOUG: consultancies with Sanofi, Takeda; Scientific Advisory Boards for Sanofi, Takeda; Medical Advisory Boards for Sanofi, Takeda. GHI: research grants from Sanofi, Takeda; Expert testimony to Sanofi, Takeda; Steering Committee for Sanofi, Takeda; Fees for serving on Steering and Data Monitoring Committees from Sanofi, Takeda. Audrey LAGADEC: Employees of Sanofi, may hold shares and/or stock options in the company., (Copyright © 2023. Published by Elsevier Inc.)
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.